
US employers consider cutting health benefits as the costs of weight-loss drugs rise
The rising costs tied to GLP-1 drugs are emerging as a strategic workforce issue.
The rising costs tied to GLP-1 drugs are emerging as a strategic workforce issue.
The results revealed multiple diet deficiencies linked to reduced food consumption and altered habits.
A study found that 76% of individuals who stopped GLP-1s still eat the same or less and many maintain healthier eating habits.
The new supplement range is dietitian-formulated and doctor-approved, providing targeted support across five key categories: protein, fiber, probiotics, multivitamins, and an all-in-one nutrient solution.
Gen Z and Millennial consumers are driving protein snack demand.
The company has invested $6.5 billion this year alone to expand its U.S. manufacturing capacity.